Vaxcyte PCVX
NASDAQ PCVX
$65.39 -0.85 (-1.28%)
As of: Oct 21, 2026 · 10:38 AM EDT

Vaxcyte (PCVX) Receivables (2021)

Updated

Vaxcyte's Receivables was $5 million in Q3 2021.

Analysis

Vaxcyte (PCVX) Receivables (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,128.06 Bn 1,096.64 Bn 19.71 Bn 23.48 Bn
2 Johnson & Johnson 615.47 Bn 534.00 Bn 17.26 Bn 19.05 Bn
3 AbbVie 504.80 Bn 477.91 Bn 12.70 Bn 13.82 Bn
4 Merck 368.45 Bn 322.83 Bn 12.21 Bn 12.56 Bn
5 Novartis Ag 298.44 Bn 262.43 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 261.92 Bn 235.60 Bn 12.86 Bn 15.68 Bn
7 Amgen 236.10 Bn 191.50 Bn 7.24 Bn 10.23 Bn
8 Gilead Sciences 190.71 Bn 164.91 Bn 6.22 Bn 5.06 Bn
9 Pfizer 170.16 Bn 116.81 Bn 10.94 Bn 12.49 Bn
10 Vaxcyte 9.49 Bn 2.99 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 5.00 Mn
API Access

Vaxcyte Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=PCVX&period=max&api_key=YOUR_API_KEY